NMPA (Class III)
Highest Safety Classification in China
Nanjing Engineering Research Center
For Anti-AMR Nanomaterials
Pioneering the Physical Antimicrobial
Pathway to Combat Global Resistance
A Government-Accredited Research Center & WHO-Registered Clinical Trial Site
Key Impact Metrics
0Years
Track record in epidemic control(SARS to COVID-19)
0
Published academic papers citingour technology
0
Viral inactivation rate
Viral inactivation rate
(Validated by CDC)
Provincial-level science and technology administrative department
Governance & Official Charter
The Center operates under the official Charter of Nanjing Engineering Research Center for Anti-AMR Nanomaterials. For legal and financial stability, we are supported by NMS Technologies Co., Ltd., which provides the industrial infrastructure.
Academic Leadership & Expert Oversight
R&D Director
Led by Prof. Huining Xiao (Fellow of the Canadian Academy of Engineering), driving biodegradable and physical antimicrobial innovations.
Strategic Advisors
Guided by top academicians Dr. Zhong Nanshan and Dr. Guo Yinglu.
Legal Entity
Responsibilities: To provide industrial infrastructure and commercialization pathways for the research of the research center.
- Supporting Unit: NMS Technology Co., Ltd.
- Establishment Date: 1993
- Responsibilities: To provide industrial infrastructure and commercialization pathways for the research of the research center.
- Our Goal: "Committed to the One Health approach: Protecting Humans, Animals, and the Environment from Drug Resistance."
Learn More
TECHNOLOGY
The Science of Physical Lysis
Unlike chemical antibiotics that interfere with metabolic pathways (leading to resistance), our core technology utilizes a positively charged nano-film. Confirmed by the University of New Brunswick, the active ingredient maintains a stable Zeta Potential of +60mV .
The Effect:This strong electrostatic field physically attracts negatively charged bacteria and ruptures their cell walls upon contact.
Learn More
Biodegradable Antimicrobial Polymers
- Patent Name: Preparation Method of a Non-leaching and Biodegradable Antimicrobial Polyester Film.
- Patent No.: ZL 2014 1 0385522.8 (Granted by China National Intellectual Property Administration).
- 1. Non-leaching : The antimicrobial agents are chemically bonded to the polymer, ensuring zero chemical release into the human body or environment, preventing secondary pollution and AMR mutation.
- 2. Biodegradable : Solves the global challenge of medical and agricultural waste, perfectly aligning with global environmental sustainability goals.
Global Intellectual Property
Our "Physical Antimicrobial Method" is secured by invention patents in major global economies
- Global (PCT): WO 2014/019452 A1
- United States: US 9,504,255 B2
- European Union: Patent No. 2881122
- Asia Pacific: China, Japan, South Korea, Australia, Singapore (Market Access)
Clinical Validation
Prevention:
Biofilm Inhibition (RCT)
Published in: Antimicrobial Resistance & Infection Control (2024)
- Study Design: Multicenter Randomized Controlled Trial.
- Key Finding: Pretreatment with our JUC Spray Dressing significantly reduces Catheter-Associated Urinary Tract Infections (CAUTI) by inhibiting bacterial biofilm formation on indwelling catheters.
CURE:
Treating "Superbugs" (Case Report)
Published in: American Journal of Therapeutics (2025)
- Challenge: An MRSA infection where Vancomycin (the "last resort" antibiotic) failed for 8 weeks.
- Outcome: The physical antimicrobial intervention achieved noticeable effects in 1 day and complete healing in 3 weeks.
Database Access
Massive Clinical Adoption:Over 1,000 academic papers have been published in the CNKI database validating the efficacy of this technology across diverse clinical departments.
Learn More
Diagnostics Innovation
The "One-Glass Method" Our physical antimicrobial technology has revolutionized clinical diagnostics. By using physical antimicrobial spray to collect bodily fluids, we developed the "One-Glass test" for prostatitis diagnosis. Supported by rigorous animal and clinical trials, it replaces the international standard "Meares–Stamey 4-glass test," significantly reducing false-positive/negative misdiagnoses and lowering patient costs.
Learn MoreNational Guideline Endorsement Recognized
For high efficacy, our physical therapy has been granted the "Strongest Recommendation" by the official Chinese Urology and Andrology Diagnosis and Treatment Guidelines.
Learn More
Regulatory Approvals
We adhere to the highest international standards for safety and quality management (ISO 13485).
China (NMPA):
Class III Medical Device Registration (No. 20163140807)
USA (FDA):
Medical Device Establishment Registration (No. 3005613390)
EU (CE):
Certified for European Market Access
South Korea (MFDS):
Import License No. 14-1699
Singapore (HSA):
Medical Device Registration
Malaysia/Honduras:
Validated Market Access
Malaysia/Honduras:
Validated Market Access
Singapore (HSA):
Medical Device Registration
South Korea (MFDS):
Import License No. 14-1699
EU (CE):
Certified for European Market Access
USA (FDA):
Medical Device Establishment Registration (No. 3005613390)
China (NMPA):
Class III Medical Device Registration (No. 20163140807)
Capacity Building & Nationwide Policy Adoption
To combat AMR effectively, we bridge the gap between innovation and clinical application. Our technology has successfully transitioned from a National Strategic Project to widespread Regional Implementation, supported by a robust continuous medical education system.Training & Capacity Building
National Strategy
Phase I: National Promotion Project (Ministry of Health)
- Authority: Designated by the Ministry of Health, P.R. China.
- Scope: Selected as a "National Appropriate Technology" (2007-2017) to replace antibiotic overuse in grassroots healthcare.
- Impact: Established the first national standard for physical infection control.
Learn More
Training & Capacity Building
Regional Implementation
Phase II: Provincial Government Adoption
Following the national directive, 10+ health commissions issued official documents to promote the technology locally.
- Scale of Adoption: Policy documents issued by Health Commissions in Jiangsu, Henan, Shandong, Hubei, Guangdong, and Beijing. Population Coverage: Covering over 400 million people across targeted regions, with the technology integrated into public hospital procurement lists.
Learn More
Training & Capacity Building
Continuous Education
Phase III: Sustainable Medical Training (CME) 2007-2025
- Current Status: Accredited "National CME Project"
- Academic Value: Awarding 8 National Credits (The highest level for physician training in China).
- Curriculum: Training clinicians on "Physical Antimicrobial Methods," shifting prescription habits away from chemical antibiotics.
Learn More
Our One Health Commitment
Curing superbug infections and preventing biofilm-related diseases without antibiotics.
Human Health
Curing superbug infections and preventing biofilm-related diseases without antibiotics.
Animal Health
Offering a viable alternative to veterinary antibiotics. We conduct non-drug infection models and treat animal enteritis, halting the spread of AMR in livestock.
Environment & Marine
Pioneering physical anti-biofouling coatings for ships and vessels, protecting marine environments from toxic chemical pollution.
Food & Agriculture
Developing biodegradable antimicrobial agricultural films and food preservation packaging materials to ensure global food safety.
Clinical Leadership & Scientific Integrity
Ye Zhangqun /Principal Investigator (PI) & Former Chair of Urology, Chinese Medical Association
Ethical Oversight: Ensured strict adherence to Good Clinical Practice (GCP) and obtained approval from the Independent Ethics Committee (Approval No. ChiECRCT-2012021).
Achievement: Led the landmark 2024 study published in Antimicrobial Resistance & Infection Control, proving efficacy against biofilm formation.
Dai Yutian / Leading Expert in Andrology & Infection Control
Education Director: Heads the Continuing Medical Education (CME) initiatives, designing curriculum to train next-generation physicians on non-antibiotic therapies.
Corporate Social Responsibility (CSR)
For over two decades, we have actively responded to global public health emergencies, provided humanitarian aid during natural disasters, and championed health equity for vulnerable populations in underdeveloped regions.
2003
2003 | Global Epidemic Response
Recognized in the Fight Against SARS During the 2003 SARS outbreak, our physical antimicrobial technology was officially designated as a "High-Tech Product for SARS Prevention" by the Chinese Ministry of Science & Technology.
• Impact: Provided critical infection control barriers for frontline healthcare workers. This established our 20-year historical legacy in national epidemic control.
National Legacy Established
2003
2005
2005
2005–2008 | Health Equity & Medical Aid
The "Western China Medical Aid Tour" In collaboration with the Chinese Medical Association, we organized continuous medical aid missions to remote and resource-limited regions, including Tibet (2005), Gansu (2006), Xinjiang (2007), and Inner Mongolia (2008).
• Impact: Trained local doctors on non-antibiotic infection control, bridging the healthcare gap. This monumental effort is officially recorded in the History of Chinese Urology.
Recorded as historical contribution
2008
2008 | Disaster Relief
Wenchuan Earthquake Humanitarian Aid In the wake of the devastating 2008 Wenchuan Earthquake, we immediately mobilized emergency medical supplies to the disaster zones.
• Impact: Delivered crucial humanitarian aid to prevent secondary, post-disaster infections in temporary shelters and field hospitals.
Humanitarian Aid Delivered
2008
2014
2014
2014 | Protecting Vulnerable Populations
Poverty Alleviation for Mountainous Schools To protect vulnerable children from infectious diseases, we launched a targeted health and medical donation initiative for Jiarong Middle School in the poverty-stricken mountainous area of Guizhou Province.
• Global Alignment: This action strictly aligns with the UN Sustainable Development Goals (SDG 1: No Poverty & SDG 3: Good Health and Well-being).
SDG 1: No Poverty
SDG 3: Good Health
2020
2020 | Pandemic Emergency Support
Emergency donation and rapid deployment support for frontline healthcare capacity.
Verified 99.99% inactivation rate
2020